Related Experiment Video
Updated: Jun 19, 2026
09:31
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Secondary amyloidosis associated with multiple sclerosis.
Seok Jae Kang1, Joo-Hark Yi, Hyun-Seok Hong
1Department of Neurology, Hanyang University College of Medicine, Guri, Korea.
Journal of Clinical Neurology (Seoul, Korea)
|October 15, 2009
Summary
This case report details the first instance of secondary amyloidosis, a rare complication, diagnosed in a multiple sclerosis (MS) patient. The findings highlight a potential link between MS and amyloidosis.
Area of Science:
- Neurology
- Nephrology
- Pathology
Background:
- Multiple sclerosis (MS) is a central nervous system demyelinating disease.
- Secondary amyloidosis is a known complication of chronic inflammatory conditions.
- No prior reports have documented secondary amyloidosis in association with MS.
Purpose of the Study:
- To report the first case of secondary amyloidosis in a patient with multiple sclerosis.
- To describe the clinical presentation and diagnostic findings.
Main Methods:
- A 41-year-old female patient with MS presented with worsening neurological symptoms and edema.
- Laboratory tests revealed nephrotic-range proteinuria and hypoalbuminemia.
- A percutaneous renal biopsy confirmed amyloid-A-type amyloidosis.
Main Results:
- The renal biopsy findings were consistent with secondary amyloid-A-type amyloidosis.
- The patient had a history of multiple sclerosis.
Conclusions:
- This case represents the first documented instance of secondary amyloidosis occurring in a patient with multiple sclerosis.
- The findings suggest a potential, previously unrecognized association between MS and secondary amyloidosis.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...